Biosimilar Development News
-
Formycon Ranibizumab Biosimilar FYB201/CIMERLI Achieved A Market Share Of 38% In The United States In December 2023
1/18/2024
Formycon AG today announced that its commercialization partner, Coherus BioSciences, Inc. has released new sales figures for CIMERLI (Ranibizumab-eqrn) in the US. Accordingly, the number of CIMERLI doses sold since its commercial launch in the US in October 2022 has increased to around 190,000 by the end of 2023.
- Results From Clinical Trials Of Two Henlius’ Novel Products Released At ASCO GI 2024 1/17/2024
-
Celltrion USA Announces Launch Of Additional Doses For YUFLYMA (adalimumab-aaty) In The U.S
1/17/2024
Celltrion USA announced today the launch of an 80mg dose of YUFLYMA (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of HUMIRA (adalimumab) biosimilar, in the United States.
-
Samsung Bioepis Releases First Quarter 2024 Us Biosimilar Market Report
1/17/2024
Samsung Bioepis Co., Ltd. today released its First Quarter 2024 Biosimilar Market Report which provides most timely information on the current status of biosimilars in the United States.
-
NeoImmuneTech Welcomes A New President For Its Development And Business
1/15/2024
NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of Luke Oh, Ph.D., as President, effective immediately.
-
All Subjects Enrolled For Intl Phase 3 Study Of Boan’s Denosumab
1/15/2024
Boan Biotech recently announced that subject enrollment for the international multicenter comparative clinical (Phase 3) study of the company’s Denosumab Injections (BA6101 and BA11021) has been completed.
-
Archimedes Announces Biosimilars First™, An Industry Leading Program To Drive Biosimilar Adoption In 2024
1/11/2024
Archimedes, a recognized leader in specialty drug management solutions, announced BiosimilarsFirst™, a program, which excludes Humira from formulary in favor of low cost, low WAC biosimilars.
-
Goodwin Releases Update To Its Comprehensive Guide To Biosimilars Litigation And Regulation In The U.S
1/10/2024
Global law firm Goodwin today announced the release of the 2023-2024 annual update to its definitive biosimilars treatise Guide to Biosimilars Litigation and Regulation in the U.S. The Guide, first launched in 2019, is the industry’s first and leading compendium of the laws and regulations governing biosimilars in the U.S., and is authored by a multidisciplinary team of experts drawn from Goodwin’s Intellectual Property, Life Sciences, FDA, Antitrust + Competition, and Appellate Litigation practices. It is published by Thomson Reuters.
-
Biosimilars Forum Welcomes Biocon Biologics As Newest Member
1/10/2024
The Biosimilars Forum has announced Biocon Biologics Ltd. (BBL), an innovation-led global biopharmaceuticals company, as its newest member.
-
Celltrion Presents Strategic Vision And Growth Plan At The 42nd Annual J.P. Morgan Healthcare Conference
1/10/2024
Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced the next phase of its strategic transformation from a developer of the world's first monoclonal antibody biosimilar to an innovative company focused on new drug development at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.